Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

OBJECTIVE: Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes. Randomised controlled trial data suggest that exenatide is as effective as insulin glargine at reducing HbA(1c )in combination th...

Descripción completa

Detalles Bibliográficos
Autores principales: Woehl, Anette, Evans, Mark, Tetlow, Anthony P, McEwan, Philip
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546382/
https://www.ncbi.nlm.nih.gov/pubmed/18694484
http://dx.doi.org/10.1186/1475-2840-7-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546382/
https://www.ncbi.nlm.nih.gov/pubmed/18694484
http://dx.doi.org/10.1186/1475-2840-7-24

Ejemplares similares